Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsCombining colchicine and statins raises some lab red flags, but serious harm is rare. A large Israeli retrospective study found that patients on both drugs had modestly higher risks for elevated muscle and liver enzymes compared to statins alone — but clinically significant events like myopathy and hospitalizations remained uncommon. The authors say the combo is generally safe when indicated, with selective lab monitoring recommended.
A large real-world study out of Israel is offering some reassurance — with caveats — for clinicians who prescribe colchicine alongside statins. Analyzing data from nearly 32,000 adults with gout and/or familial Mediterranean fever (FMF), researchers found that the combination was linked to modestly higher risks for abnormal creatine kinase (CK) and liver enzyme (ALT) levels compared to statins alone. However, the absolute rates of serious events like clinical myopathy and related hospitalizations were low across all groups.
The study, published in Arthritis Care & Research, used propensity score matching to compare four groups: no treatment, colchicine only, statins only, and both. While the combo group consistently showed the highest relative risks for muscle and liver abnormalities, the authors emphasized that the incremental risk beyond statins alone was small.
Key Takeaways:
Why it matters: Many patients with gout or FMF also need statins for cardiovascular protection. This study supports continuing that combination when clinically appropriate, while flagging the importance of patient-specific risk assessment — particularly renal function — and selective lab monitoring.
